Upregulation of a lymphoid serine protease in kidney allograft recipients

Upregulation of a lymphoid serine protease in kidney allograft recipients. The presence of a putative, cytotoxicity-linked lymphoid serine esterase (SE) has been studied in 79 kidney graft recipients. Peripheral blood lymphocytes (PBL) bearing an N-α-benzyloxy carbonyl-L-lysine thiobenzyl ester (BLT)-specific SE were evaluated by a novel cytochemical staining method. A characteristic of post-allograft patients was an increased presence of SE containing granules in PBL. In 46 patients with stable graft function SE + PBL were 33.41 ± 10.34% (controls: 26.30 ± 5.22%, P < 0.0025), SE + CD4+ 4.32 ± 3.85% (controls 2.13 ± 1.52%, P < 0.0025) and SE + CD8+ T cells 47.68 ± 18.64% (controls: 28.50 ± 6.50%, P < 0.0005). In those graft recipients undergoing a rejection episode a marked upregulation of SE activity could be observed when compared to the stable graft group: SE + PBL were 59.91 ± 10.89% (P < 0.0005), SE + CD8+ 74.30 ± 10.79% (P < 0.0005) and SE + CD4+ T cells 28.56 ± 13.50% (P < 0.0005). In 10 cases this increase of SE activity was observed with a time lag of up to 37 days prior to the onset of clinical or biopsy proven rejections, promptly decreasing in response to methylprednisolone antirejection therapy. In patients with recurrent rejection episodes and subsequent graft loss, a repeating increase of SE activity indicated a failure of therapeutic agents. In allograft recipients suffering from a viral infection, usually identified as cytomegalovirus, in comparison to those with a rejection episode, high levels of SE + PBL were found (67.10 ± 12.72%, P < 0.1) due to the upregulation of SE + CD8+ lymphocytes (76.30 ± 12.05%, P < 0.35) and a low-grade SE activity of CD4+ cells (12.20 ± 8.13%, P < 0.0025) in concordance with an inverted CD4/CD8 ratio. Our results underline the assumption that BLT-SE is closely associated to lymphocyte activation/cytotoxic function.